Rapport Market Capitalization from 2010 to 2025

RAPP Stock   12.69  0.18  1.44%   
Rapport Therapeutics, Market Cap yearly trend continues to be relatively stable with very little volatility. Market Cap is likely to drop to about 1.7 B.
Check Rapport Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rapport Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 69.8 K, Interest Expense of 0.0 or Other Operating Expenses of 25.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 34.79. Rapport financial statements analysis is a perfect complement when working with Rapport Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Rapport Therapeutics, Correlation against competitors.

Latest Rapport Therapeutics,'s Market Capitalization Growth Pattern

Below is the plot of the Market Cap of Rapport Therapeutics, Common over the last few years. It is Rapport Therapeutics,'s Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rapport Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 762.25 M10 Years Trend
Slightly volatile
   Market Cap   
       Timeline  

Rapport Market Capitalization Regression Statistics

Arithmetic Mean1,128,576,923
Geometric Mean957,956,819
Coefficient Of Variation76.20
Mean Deviation597,653,254
Median760,790,306
Standard Deviation859,943,544
Sample Variance739502.9T
Range2.7B
R-Value0.59
Mean Square Error512394.1T
R-Squared0.35
Significance0.02
Slope107,361,767
Total Sum of Squares11092543.5T

Rapport Market Capitalization History

20251.7 B
20243.1 B
20233.4 B

About Rapport Therapeutics, Financial Statements

Rapport Therapeutics, shareholders use historical fundamental indicators, such as Market Capitalization, to determine how well the company is positioned to perform in the future. Although Rapport Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Rapport Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Rapport Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Rapport Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.

Pair Trading with Rapport Therapeutics,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rapport Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics, will appreciate offsetting losses from the drop in the long position's value.

Moving together with Rapport Stock

  0.61EQ EquilliumPairCorr
  0.66ME 23Andme HoldingPairCorr
  0.66VALN Valneva SE ADRPairCorr

Moving against Rapport Stock

  0.91DRTS Alpha Tau MedicalPairCorr
  0.78SRZNW Surrozen WarrantPairCorr
  0.7DMAC DiaMedica TherapeuticsPairCorr
  0.69VCEL Vericel Corp OrdPairCorr
  0.68CDIOW Cardio DiagnosticsPairCorr
The ability to find closely correlated positions to Rapport Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rapport Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rapport Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rapport Therapeutics, Common to buy it.
The correlation of Rapport Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rapport Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rapport Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rapport Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Rapport Stock Analysis

When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.